TEFCA™, America’s National Interoperability Network, Reaches Nearly 500 Million Health Records Exchanged as HHS Leverages Technology and AI to Lower Costs and Reduce Burden - HHS.gov

Expert analysts and the latest news keep readers in the game

Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026. Hormone therapy has proven to be successful in managing a wide array of bothersome menopause symptoms, especially hot flashes. A challenge, however, is that fluctuations in estrogen levels may influence migraines.